Recent Advances in Adeno-Associated Virus-Mediated Gene Therapy and Vaccine Development
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (20 October 2025) | Viewed by 4746
Special Issue Editors
Interests: HBV; RNAi; siRNA; shRNA; miRNA; cccDNA
Interests: adeno-associated viral vectors; adenoviral vectors; antiviral gene therapy; antiviral vaccine development; hepatitis B virus; hepatitis B virus infection models
Special Issue Information
Dear Colleagues,
AAVs have become the key to gene therapy development in recent years. Multiple lines of evidence highlight AAVs as the safest gene therapy delivery vehicle, and several AAV-based products have been approved for clinical applications. However, there has also been evidence of toxicities in patients following AAV therapy, suggesting that AAVs are not a perfect fit for all. Because AAVs have been thought to stimulate a weaker immune response, they have been overlooked for vaccine development. However, studies illustrating the potential of AAVs as vaccines are starting to emerge. Whether the inherent long-term transgene expression of AAVs could be an advantage or limit their application in vaccine development is still being explored. This Special Issue aims to collate recent findings with regard to the efficacy, safety, and feasibility of using AAVs as gene therapeutics or vaccines against a variety of communicable and non-communicable diseases.
Prof. Dr. Patrick Arbuthnot
Dr. Betty Maepa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- AAV
- gene therapy
- vaccines
- infectious diseases
- communicable diseases
- genetic disorders
- non-communicable diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
